Provided by Tiger Trade Technology Pte. Ltd.

ABVC BioPharma, Inc.

0.9700
-0.0900-8.49%
Pre-market: 1.030.0600+6.19%04:53 EDT
Volume:94.60K
Turnover:94.86K
Market Cap:25.85M
PE:-3.40
High:1.08
Open:1.08
Low:0.9500
Close:1.06
52wk High:3.40
52wk Low:0.7069
Shares:26.65M
Float Shares:21.83M
Volume Ratio:0.71
T/O Rate:0.43%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2855
EPS(LYR):-0.3933
ROE:-69.86%
ROA:-22.85%
PB:2.51
PE(LYR):-2.47

Loading ...

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Aug 01

Buy Rating Reaffirmed on Contineum Therapeutics with Unchanged $26 Price Target, Backed by Advancing IPF and MDD Pipelines

TIPRANKS
·
Aug 01

ABVC Biopharma Announces Special Shareholder Meeting

Reuters
·
Jul 29

Greenbrook Opens National Center of Excellence for Advanced Interventional Psychiatry in Rockville, Maryland

GlobeNewswire
·
Jul 28

US FDA Approves Otsuka's Novel ADHD Drug Simtriyo for Market Launch

Deep News
·
Jul 28

Helus Pharma Fast-Tracks Phase 3 Enrollment for MDD Drug HLP003

TIPRANKS
·
Jul 22

Is Axsome Therapeutics (AXSM) Reframing Its CNS Strategy With Pediatric Solriamfetol Trial Expansion?

Simply Wall St.
·
Jul 14

Supernus Celebrates Five-Year Anniversary of Qelbree® FDA Approval, Continuing to Deliver on Real-World Experience in ADHD

GlobeNewswire
·
Jul 14

Appeals Court Revives Lawsuits Alleging Tylenol Causes Autism and ADHD

Dow Jones
·
Jul 14

Axsome Therapeutics: SUNOSI IP De-Risked, ADHD Phase 3 Expansion Supports Reaffirmed $290 12-Month Price Target and Buy Rating

TIPRANKS
·
Jul 08

Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD)

GlobeNewswire
·
Jul 07

Neuronetics to Participate in a Panel Discussion at B. Riley Securities' Mind, Muscle & Vision Summit on July 16, 2026

GlobeNewswire
·
Jul 06

The Bull Case For Axsome Therapeutics (AXSM) Could Change Following Phase 3 ADHD Trial And Index Moves

Simply Wall St.
·
Jul 06

ABVC Biopharma Replaces Auditor Simon & Edward with Kreit & Chiu for 2026 Audit

Reuters
·
Jul 03

Cingulate Inc. (NASDAQ: CING) Added to Russell 3000E®

GlobeNewswire
·
Jul 02

BrainsWay Presents Positive Data from Largest Real-World Study of Deep TMS™ in Patients with Comorbid PTSD and Major Depressive Disorder

GlobeNewswire
·
Jun 29

BlinkLab Says European ADHD Study Completes Participant Recruitment, Shares Fall 3%

MT Newswires Live
·
Jun 26

BlinkLab Nears Final Analysis in European ADHD Study After Completing Data Collection

TIPRANKS
·
Jun 26

Analyst Raises 12‑Month Target and Reiterates Buy on Definium After Best-in-Class MDD Trial Results and Reduced Risk Adjustment

TIPRANKS
·
Jun 23

Brisebois Raises Definium Therapeutics Price Target to $63 on Strong DT120 ODT Phase 3 Data and Reduced MDD/GAD Risk

TIPRANKS
·
Jun 22